I was wondering the same thing when I saw that item. But, I would think any new 'science' could take years to get through the FDA. It does address the same cancers SGEN is working on.
This morning, the doctors were asked about knee replacements, options, and the best alternative. Without hesitation, the doctor mentioned Makoplasty as being the best alternative including total knee replacement.
TASER announces X2, X26 CEW orders
TASER announced several significant orders for more than 409 TASER Smart Weapon Platforms and 955 TASER X26 Conducted Electrical Weapons, or CEWs, along with various related equipment. Smart TASER CEW orders include Sunnyvale Department of Public Safety order for 210 TASER X26P CEWs, Richmond County Sheriff's Office order for 136 TASER X2 CEWs, Tulsa Police Department order for 33 X2s, and Garfield County Sheriff's Office order for 30 X2s. TASER X26 CEW orders include United Kingdom orders for 100 X26s, 16,000 TASER cartridges and 6,000 XDPMs, U.S. Army order for 500 X26s, Philadelphia Police Department, PA order for 225 X26s, and unnamed U.S. federal law enforcement agency order for 130 X26s and 24,720 TASE R cartridges. These orders are expected to ship in the first half of 2013.
August 9, 2012
07:58 EDT SGEN theflyonthewall.com: Seattle Genetics shares should be bought on weakness, says RBC Capital
RBC Capital believes that Seattle Genetics' flat Adcetris sales could raise concerns about the drug's outlook. But the firm thinks that the company's guidance is achievable, while the company should remain a core biotech holding. :theflyonthewall.com
If you actually care to know what trials Seattle Genetics are engaged in, follow the link and type in 'Seattle Genetics'. This is what you will find.
Found 74 studies with search of:
Saw an item cross the news wire today suggesting that chemo could actually promote cancer development. Could it be that ADC science might get a huge boost from this. Just wondering. Any thoughts?
"Conducted by researchers at the Fred Hutchinson Cancer Research Center in Seattle, the study analyzed fibroblast cells, which are critically involved in wound healing and collagen production. The scientists found chemotherapy caused DNA damage that, in turn, triggered the fibroblasts to produce 30 times more WNT 16B protein than normal.
According to the study, the WNT 16B protein helps cancer cells to grow and invade surrounding tissue, as well as developing a resistant to chemotherapy.
July 27, 2012
07:40 EDT TASR theflyonthewall.com: TASER price target raised to $8 from $6 at Craig-Hallum
Craig-Hallum upgraded TASER citing its exceptional cash flow and margins, accelerating growth, a significant upgrade cycle, and a new video product that could be a "cash machine." Shares are Buy rated. :theflyonthewall.com
July 1, 2012
22:09 EDT Z theflyonthewall.com: Please Act Accordingly's Safalow likes Briggs & Stratton, Zillow, Barron's says
Barron's interviewed Bradley Safalow, founder of investment-idea service, Please Act Accordingly. Safalow employs exhaustive study of companies and industries and calculates that 70% of his long and short ideas have produced positive absolute returns. Safalow's PICKS: Briggs & Stratton (BGG) and Zillow (Z). PANS OpenTable (OPEN), ITT Industries (ESI), Corinthian Colleges (COCO), Washington Post (WPO), Verifone (PAY), Heartland Payments (HPY), Global Payments (GPN) and Toro (TTC). Reference Link :theflyonth ewall.com
Seattle Genetics Shares Continue To Impress - And It's Not Too Late To Buy
June 8, 2012
08:43 EDT SGEN
Seattle Genetics price target raised to $25 from $20 at Needham
Based on data presented at ASCO from ongoing Adcetris clinical trials, Needham believes Seattle Genetics may succeed in adding retreatment to the drug's label later this year. The firm raised its price target on the stock to $25, citing its view that Adcetris may fill an important role in oncology, and keeps a Buy rating on the stock. :theflyonthewall.com
We seem to be at rather lofty levels for the pps right now but, as I recall, Oppenheimer has a price target of 26 on the stock. And, a couple of others have it higher as well. Fwiw, of course.
Cramer Interviews Seattle Genetics CEO
Published: Tuesday, 5 Jun 2012 | 6:50 PM ET
By: Kirsten Chang
Special to CNBC
While economies everywhere continue to face a global slowdown, investors should turn to the safety of stocks in a recession-proof sector, Jim Cramer said Tuesday on CNBC's "Mad Money." He cited Seattle Genetics as the perfect example of one such stock.
With a market capitalization of $2.4 billion, Seattle Genetics [SGEN 20.865 1.045 (+5.27%) ] is a small company, but Cramer thinks it’s worth speculating on.
The Bothell, Wash.-based firm champions the use of innovative biotechnology — like engineered antibodies to target and kill cancer cells while sparing healthy cells. And though the stock isn't profitable just yet, it does have one drug — Adcetris — already on the market and is expected to start raking in material revenues in 2014.
Cramer also noted that at the American Society of Clinical Oncology conference, Seattle Genetics released "bullish phase two data" about the use of Adcetris to treat other types of lymphoma, in addition to the Hodgkin's and large cell strains of lymphoma the drug has already successfully treated.
ASCO spotlight: Antibody-drug conjugates arrive
June 1, 2012 | By Ryan McBride
The past year has been one worth celebrating for developers of antibody-drug conjugates (ADCs), which are drugs that marry an anti-cancer toxin to a targeted antibody to kill tumors with fewer side effects than traditional treatments. In a New York Times article, veteran reporter Andrew Pollack features this emerging class of therapies and the long haul required to advance some of the drugs.
At the major American Society of Clinical Oncology meeting this weekend in Chicago, plan to hear a lot about T-DM1 from Roche's ($RHHBY) Genentech and partner ImmunoGen ($IMGN). Genentech plans to present Phase III data on the drug, which is made by linking its blockbuster antibody Herceptin with a chemotherapy agent. The drug has already shown that it provides longer progression-free survival in patients with HER2-positive breast cancer with about half the cases of serious side effects as treatment with Herceptin and chemotherapy given together but not linked, the Times reported.
ImmunoGen provides the linker and anti-cancer toxin in the treatment, and T-DM1 could become the first approved drug that uses the developer's technology. ImmunoGen could follow in the footsteps of rival Seattle Genetics ($SGEN), which gained its first approval last summer for an ADC called Adcetris to combat forms of lymphoma. As Pollack writes, a key for these companies has been keeping the anti-cancer toxins linked to the antibodies in the bloodstream until the treatments reach their targets. In 2010 Pfizer ($PFE) pulled from the market an ADC called Mylotarg, which had difficulty staying intact before it hit cancer cells.
Both Seattle Genetics and ImmunoGen have landed plenty of pharma partnerships on the strength of their technologies, and venture investors have placed several bets on new developers of ADC. In March, for instance, biotech investor Celtic Therapeutics committed $50 million to back ADC Therapeutics, a next-generation developer of the products.
"I don't think there is a major pharma or a midsized pharma with interest in cancer that doesn't have a program or isn't scrambling to put one together," Stephen Evans-Freke, a managing general partner at Celtic, told the Times.
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies
One of the big dreams in biotech over the past 35 years has been to make drugs that work like “smart bombs” by destroying tumors while minimizing collateral damage. Scientists have learned this is no easy thing, but now that a couple of these types of drugs have been shown to work, a new wave of companies is emerging to see if they can finally turn this vision into reality.
Targeted antibody drugs have been around for a long time, and have been shown to do a lot of good for patients. Some of the world’s best-selling medicines are designed to specifically hone in on cancer cells while mostly sparing healthy tissues. Yet it’s only been in the last several years that a couple of companies—Seattle Genetics and Genentech—have shown proof in clinical trials that they can go a step further than what’s been done with so-called “naked” antibodies. The concept is simple: Take a regular antibody, link it to a toxin, and design the combination so that it unleashes a killer payload on tumors. Done right, you ought to have a drug with more punch than traditional antibodies or chemotherapy.
May 9, 2012
07:40 EDT SGEN theflyonthewall.com: Seattle Genetics shares should be bought on weakness, says RBC Capital
After Seattle Genetics reported weaker than expected Q1 Adcetris sales, RBC Capital still believes that the company has multiple market expansion opportunities. The firm thinks that the company could announce new data at ASCO that will provide a positive catalyst for the stock, and it maintains an Outperform rating on the shares. :theflyonthewall.com
07:26 EDT SGEN theflyonthewall.com: Seattle Genetics price target lowered to $21 from $24 at Leerink
Leerink lowered its estimates and price target for Seattle Genetics after the company's guidance missed expectations, but said it remains optimistic about the company's long-term prospects. The firm keeps an Outperform rating on the stock. :theflyonthewall.com